EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

OBJECTIVE: Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology—Magnitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiesewetter, Barbara, Cherny, Nathan I, Boissel, Nicolas, Cerisoli, Francesco, Dafni, Urania, de Vries, Elisabeth G E, Ghia, Paolo, Gökbuget, Nicola, González-Calle, Verónica, Huntly, Brian, Jäger, Ulrich, Latino, Nicola Jane, Douillard, Jean-Yves, Malcovati, Luca, Mateos, María-Victoria, Ossenkoppele, Gert J, Porkka, Kimmo, Raderer, Markus, Ribera, Josep-Maria, Scarfò, Lydia, Wester, Ruth, Zygoura, Panagiota, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003483/
https://www.ncbi.nlm.nih.gov/pubmed/31958292
http://dx.doi.org/10.1136/esmoopen-2019-000611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003483/
https://www.ncbi.nlm.nih.gov/pubmed/31958292
http://dx.doi.org/10.1136/esmoopen-2019-000611

Ejemplares similares